Table 4 Phase II studies of antiangiogenic therapy
From: Targeted therapies in breast cancer: are heart and vessels also being targeted?
Study | Treatment | Line of therapy | Number of patients | Hypertension (grade 3 or 4) (%) | CHF NYHA class III or IV (%) | Thrombotic events (grade 3 or 4) (%) |
|---|---|---|---|---|---|---|
Miller et al. [89] | Vandetanib monotherapy | 2, 3 | 46 | 0 | 0 | 0 |
Boer et al. [90] | Vandetanib + docetaxel versus vandetanib | 1 | 64 | 0 | 0 | 0 |
Rugo et al. [91] | Axitinib + docetaxel versus docetaxel | 1 | 168 | 5 | 0 | 0 |
Taylor et al. [92] | Pazopanib monotherapya | 1, 2, 3 | 18 | 14 | 0 | 0 |
Moreno-Aspitia et al. [111] | Sorafenib monotherapy | 1, 2 | 23 | 0 | 0 | 0 |
Baselga et al. [86] | Sorafenib + capecitabine versus capecitabine | 1, 2 | 229 | 0 | 0 | 0 |
Isaascs et al. [87] | Sorafenib + anastrozole versus anastrozolea | 1, 2 | 35 | 11 | 0 | 0 |
Gradishar et al. [88] | Sorafenib + paclitaxel versus paclitaxel | 1 | 237 | 0 | 0 | 0 |